Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1
Objective: To determine whether digital biomarker sensor data detect slowing in progression of core motor features of Parkinson’s disease (PD) in individuals with early PD…SB-0107, a drug repurposing opportunity identified through machine learning, shows the potential to treat Parkinson’s disease motor disability and levodopa-induced dyskinesia in rat and primate models
Objective: To characterize the effects of a computationally identified small molecule in rat and primate models of Parkinson’s disease-associated motor deficits and treatment-associated complications. Background:…Assessment of Fluctuating Parkinson’s Disease with Sensor-Based Home Monitoring-Feasibility Results
Objective: To implement home-based monitoring (HBM) using wearable devices, a smartphone dedicated app and patient reported outcomes in order to provide a more comprehensive picture…Istradefylline/L-DOPA combination therapy for Parkinson’s disease and blood markers of glycolytic energy homeostasis
Objective: To clarify the potential to preserve glycolytic energy homeostasis (GEH) with the Istradefylline combined to L-DOPA (IST-LD), and to prevent LD-induced weight loss and…Influence of demographic characteristics on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study
Objective: This post-hoc analysis evaluated the influence of baseline demographic characteristics (i.e., age and gender) on the response to opicapone (OPC) in Parkinson’s disease (PD)…Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of monoamine-oxidase-B inhibitors (MAO-B) and dopamine agonists (DA): findings from the real-world OPTIPARK study
Objective: This post-hoc analysis evaluated the effectiveness of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations (MF) according to baseline use of monoamine-oxidase-B…Predictive factors of LCIG infusion therapy adherence – a single-center study of 103 consecutive LCIG patients
Objective: The objectives of this study were to find predictive factors for early dropout from levodopa-carbidopa intestinal gel (LCIG) infusion in advanced Parkinson’s disease (PD)…Plasma Short-Chain Fatty Acids Differences in Multiple System Atrophy from Parkinson’s Disease
Objective: We aimed to investigate the plasma short-chain fatty acids (SCFAs) in multiple system atrophy (MSA) patients and to identify the potential differential diagnostic ability.…Predictors of survival in Progressive Supranuclear Palsy in a Tunisian cohort
Objective: To investigate survival and its determinants in a Tunisian cohort of Progressive Supranuclear Palsy (PSP). Background: PSP is a neurodegenerative tauopathy characterized by faster…TELEMONITORING OF THE ORAL HEALTH OF PARKINSONIANS DURING THE NEW CORONAVIRUS PANDEMIC
Objective: To Promote telemonitoring of the oral health of people with Parkinson disease in times of Covid-19. Background: Among the most affected population by Covid-19…
- « Previous Page
- 1
- …
- 122
- 123
- 124
- 125
- 126
- …
- 132
- Next Page »